Bluejay Diagnostics advances Symphony IL-6 test as SYMON-II enrollment concludes
Bluejay Diagnostics, Inc. has completed enrollment in its 750-patient SYMON-II clinical validation study, moving the investigational Symphony IL-6 test into the data-cleaning, sample-testing and statistical-analysis phase that will determine whether the company has a credible basis for a U.S. regulatory submission. The Nasdaq-listed diagnostics developer said enrollment finished earlier than originally anticipated across participating healthcare